Advertisement

EPMA Journal

, Volume 10, Issue 4, pp 317–335 | Cite as

Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice

  • Rostyslav BubnovEmail author
  • Lidiia Babenko
  • Liudmyla Lazarenko
  • Maryna Kryvtsova
  • Oleksandr Shcherbakov
  • Nadiya Zholobak
  • Olga Golubnitschaja
  • Mykola Spivak
Research

Abstract

Background

Microbiome modulation is a pillar intervention to treat metabolic syndrome, prestages, and cascade of related pathologies such as atherosclerosis, among others. Lactobacillus and Bifidobacterium probiotic strains demonstrate efficacy to reduce obesity, dyslipidemia, and improve metabolic health. Novel prebiotic substances composed with known probiotics may strongly synergize health benefits to the host. The aim of this study was to evaluate beneficial effects of Lactobacillus and Bifidobacterium strains (probiotics) if composed with nanoceria (potential prebiotic) to reduce cholesterol levels and restore gut microbiota in obese mice.

Materials and Methods

Two lines of mice were used in the study: BALB/c mice (6–8 weeks, 18–24 g) and CBA mice (11–12 months, 20–26 g); experimental animals were fed by fat-enriched diet 3 weeks before the evaluation. Animals were divided into groups to test probiotic strains and nanoceria. All groups received probiotic strains orally and cerium dioxide orally or intravenously in various composition. A group of untreated animals was used as a control. Cholesterol level and gut microbiota of mice were studied.

Results

Cerium dioxide nanoparticles, probiotic strain L. casei ІМV В-7280, and composition B. animalis VKB/B. animalis VKL applied separately and in different combinations all reduced at different levels free and bound cholesterol in blood serum of mice fed by fat-enriched diet. The combination of 0.01 M nanoceria and probiotic strain L. casei ІМV В-7280 resulted in the fastest cholesterol level decrease in both young and mature animals. Oral administration of CeO2 applied alone reduced the number of microscopic fungi in the gut of mice and Gram-positive cocci (staphylococci and/or streptococci). Application of L. casei IMV B-7280 as a probiotic strain increased most significantly the number of lactobacilli and bifidobacteria in the gut of mice. The most significant normalization of gut microbiota was observed after oral administration of alternatively either L. casei IMV B-7280 + 0.1 M CeO2 or L. casei IMV B-7280 + 0.01 M CeO2.

Conclusion

Dietary application of nanoceria combined with probiotic strains L. casei IMV B-7280, B. animalis VKB, and B. animals VKL has significantly reduced both free and bound cholesterol levels in serum. Simultaneous administration of probiotics and cerium nanoparticles as a prebiotic, in various combinations, significantly enhanced positive individual effects of them on the gut microbiota spectrum. The presented results provide novel insights into mechanisms behind nutritional supplements and open new perspectives for application of probiotics combined with substances demonstrating prebiotic qualities benefiting, therefore, the host health. Follow-up translational measures are discussed to bring new knowledge from lab to the patient. If validated in a large-scale clinical study, this approach might be instrumental for primary and secondary prevention in obese individual and patients diagnosed with diabetes. To this end, individualized prediction and treatments tailored to the person are strongly recommended to benefit the health condition of affected individuals.

Keywords

Predictive preventive personalized medicine Nanoceria Nanoparticles Prebiotic Probiotic Obesity Metabolic syndrome Atherosclerosis Animal model Improved metabolism In vivo Microbiome Gut microbiota Lactobacillus Bifidobacterium Cholesterol Phenotype 

Notes

Acknowledgments

The study was conducted with the support of the State Agency on Science, Innovations and Informatisation of Ukraine.

Authors’ contributions

Rostyslav Bubnov created concepts and designed the study, participated in experiments, performed ultrasound investigations and analytical procedures, and drafted discussion and outlook. Lidiia Babenko and Liudmyla Lazarenko performed experiments on animals, corresponding analysis, and statistical evaluation, and created the first draft of manuscript. Maryna Kryvtsova, Nadiya Zholobak, and Oleksandr Shcherbakov participated in analytical approaches. Olga Golubnitschaja contributed to main concepts of the study, data interpretation and multidisciplinary aspects, and strengthened the expertise related to predictive, preventive, and personalized medicine. Mykola Spivak supervised the project and contributed to the data interpretation.

All authors read and approved the final manuscript.

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

This study has been approved by the ethics committee of institutional review board and Special Academic Council on Doctoral Thesis of D.K. Zabolotny Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine (protocol N 7 issued 03.07.2018).

No human subjects were included into the study.

References

  1. 1.
    Duarte AA, Mohsin S, Golubnitschaja O. Diabetes care in figures: current pitfalls and future scenario. EPMA J. 2018;9(2):125–31.  https://doi.org/10.1007/s13167-018-0133-y.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    World Health Organization (2018). Obesity and overweight. Fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. (Accessed 25.10.2019).
  3. 3.
    World Health Organization (2017). Cardiovascular diseases (CVDs). Fact sheet. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). (Accessed 25.10.2019).
  4. 4.
    Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14.  https://doi.org/10.1186/1878-5085-3-14.
  5. 5.
    Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Costigliola V. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23.  https://doi.org/10.1186/s13167-016-0072-4.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Golubnitschaja O, Costigliola V, EPMA. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6(1):4. doi: 10.1186/s13167-015-0026-2.Google Scholar
  7. 7.
    Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV. Probiotics and immunity: provisional role for personalized diets and disease prevention. EPMA J. 2015;6:14.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ndumele CE, Nasir K, Conceiçao RD, Carvalho JAM, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927–32.  https://doi.org/10.1161/ATVBAHA.111.228262.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Crit Pathw Cardiol. 2005;4(4):198–203.PubMedCrossRefGoogle Scholar
  10. 10.
    Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian Population. Int J Med Sci. 2016;13(1):25–38.  https://doi.org/10.7150/ijms.13800.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Reid G, Abrahamsson T, Bailey M, Bindels LB, Bubnov R, Ganguli K, et al. How do probiotics and prebiotics function at distant sites? Benefic Microbes. 2017;20:1–14.  https://doi.org/10.3920/BM2016.0222.CrossRefGoogle Scholar
  12. 12.
    Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Wong RG, Urquhart BL, et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis. 2018;273:91–7.  https://doi.org/10.1016/j.atherosclerosis.2018.04.015.PubMedCrossRefGoogle Scholar
  13. 13.
    Reijnders D, Goossens GH, Hermes GD, Neis EP, van der Beek CM, Most J, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 2016;24(1):63–74.  https://doi.org/10.1016/j.cmet.2016.06.016.PubMedCrossRefGoogle Scholar
  14. 14.
    Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35:566–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Jobin C. Precision medicine using microbiota. Science. 2018;359(6371):32–4.  https://doi.org/10.1126/science.aar2946.PubMedCrossRefGoogle Scholar
  16. 16.
    Bubnov RV, Babenko LP, Lazarenko LM, Mokrozub VV, Demchenko OA, Nechypurenko OV, et al. Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on holesterol levels, liver morphology and the gut microbiota ino bese mice. EPMA J. 2017;8(4):357–76.  https://doi.org/10.1007/s13167-017-0117-3.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Babenko LP, Sokolviak OY, Мokrozub VV, Nechypurenko OO, Demchenko OM, Bubnov RV, et al. Lactobacillus and Bifidobacterium probiotic strains reduce cholesterol levels and affect the gut microbiota in obese mice. United European Gastroenterol J. 2016;4(5S):A374–5.  https://doi.org/10.1177/2050640616663689.CrossRefGoogle Scholar
  18. 18.
    Bubnov RV, Babenko LP, Lazarenko LM, Mokrozub VV, Spivak MY. Specific properties of probiotic strains: relevance and benefits for the host. EPMA J. 2018.  https://doi.org/10.1007/s13167-018-0132-z.PubMedCrossRefGoogle Scholar
  19. 19.
    Wu Y, Zhang Q, Ren Y, Ruan Z. Effect of probiotic Lactobacillus on lipid profile: a systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2017;12(6):e0178868.  https://doi.org/10.1371/journal.pone.0178868.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Bendali F, Kerdouche K, Hamma-Faradji S, Drider D. In vitro and in vivo cholesterol lowering ability of Lactobacillus pentosus KF923750. Benefic Microbes. 2017;8(2):271–80.  https://doi.org/10.3920/BM2016.0121.CrossRefGoogle Scholar
  21. 21.
    Song M, Park S, Lee H, Min B, Jung S, Park S, et al. Effect of Lactobacillus acidophilus NS1 on plasma cholesterol levels in diet-induced obese mice. J Dairy Sci. 2015;98(3):1492–501.  https://doi.org/10.3168/jds.2014-8586.PubMedCrossRefGoogle Scholar
  22. 22.
    Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917.  https://doi.org/10.1155/2012/902917.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Michael DR, Davies TS, Moss JWE, Calvente DL, Ramji DP, Marchesi JR, et al. The anti-cholesterolaemic effect of a consortium of probiotics: an acute study in C57BL/6J mice. Sci Rep. 2017;7(1):2883.  https://doi.org/10.1038/s41598-017-02889-5.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Greany KA, Bonorden MJ, Hamilton-Reeves JM, McMullen MH, Wangen KE, Phipps WR, et al. Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr. 2008;62:232–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M. Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS One. 2015;10(10):e0139795.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8(1):52.  https://doi.org/10.1186/s13073-016-0300-5.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Garcia SL, Buck M, McMahon KD, Grossart HP, Eiler A, Warnecke F. Auxotrophy and intrapopulation complementary in the ‘interactome’ of a cultivated freshwater model community. Mol Ecol. 2015;24(17):4449–59.  https://doi.org/10.1111/mec.13319.PubMedCrossRefGoogle Scholar
  28. 28.
    Garcia SL, Stevens SLR, Crary B, Martinez-Garcia M, Stepanauskas R, Woyke T, et al. Contrasting patterns of genome-level diversity across distinct co-occurring bacterial populations. ISME J. 2017;12:742–55.  https://doi.org/10.1038/s41396-017-0001-0.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Papadimitriou K, Zoumpopoulou G, Foligné B, Alexandraki V, Kazou M, Pot B, et al. Discovering probiotic microorganisms: in vitro, in vivo, genetic and omics approaches. Front Microbiol. 2015;6:58.  https://doi.org/10.3389/fmicb.2015.00058.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014;11(5):4745–67.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    van den Nieuwboer M, Browne PD, Claassen E. Patient needs and research priorities in probiotics: a quantitative KOL prioritization analysis with emphasis on infants and children. Pharma Nutri. 2016;4(1):19–28.CrossRefGoogle Scholar
  32. 32.
    Lyu Q, Hsu C-C. Can diet influence our health by altering intestinal microbiota-derived fecal metabolites? mSystems. 2018;3(2):e00187–17.  https://doi.org/10.1128/mSystems.00187-17.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Malhotra A, Redberg RF, Meier P. Saturated fat does not clog the arteries: coronary heart disease is a chronic inflammatory condition, the risk of which can be effectively reduced from healthy lifestyle interventions. Br J Sports Med. 2017;51:1111–2.PubMedCrossRefGoogle Scholar
  34. 34.
    Malhotra A, Noakes T, Phinney S. It is time to bust the myth of physical inactivity and obesity: you cannot outrun a bad diet. Br J Sports Med. 2015;49:967–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–53.  https://doi.org/10.1016/S2213-8587(18)30288-2.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Golubnitschaja O. Flammer syndrome in the global context – the “U-Shape” of health risks. Flammer syndrome – from phenotype to associated pathologies, prediction, prevention and personalisation. Springer 2019, ISBN 978-3-030-13549-2 ISBN 978-3-030-13550-8 (eBook),  https://doi.org/10.1007/978-3-030-13550-8.Google Scholar
  37. 37.
    Bubnov R and Golubnitschaja O. Flammer syndrome, disordered eating and microbiome: interrlations, complexity of risks and individual outcomes. In book. Flammer syndrome – from phenotype to associated pathologies, prediction, prevention and personalisation. Springer 2019, ISBN 978-3-030-13549-2 ISBN 978-3-030-13550-8 (eBook),  https://doi.org/10.1007/978-3-030-13550-8 Google Scholar
  38. 38.
    Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491–502.  https://doi.org/10.1038/nrgastro.2017.75.PubMedCrossRefGoogle Scholar
  40. 40.
    Marco ML, Heeney D, Binda S, Cifelli CJ, Cotter PD, Foligné B, et al. Health benefits of fermented foods: microbiota and beyond. Curr Opin Biotechnol. 2017 Apr;44:94–102.  https://doi.org/10.1016/j.copbio.2016.11.010].PubMedCrossRefGoogle Scholar
  41. 41.
    Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13(5):278–88.  https://doi.org/10.1038/nrendo.2016.210.PubMedCrossRefGoogle Scholar
  42. 42.
    Konopelniuk VV, Goloborodko II, Ishchuk TV, Synelnyk TB, Ostapchenko LI, Spivak MY, et al. Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model—comparative study. EPMA J. 2017;8:377–90.  https://doi.org/10.1007/s13167-017-0098-2.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J. 2013;4(1):20 -10.1186/1878-5085-4-20.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Nido SA, Shituleni SA, Mengistu BM, Liu Y, Khan AZ, Gan F, et al. Effects of selenium-enriched probiotics on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in mice fed a high-fat diet. Biol Trace Elem Res. 2016;171(2):399–409.  https://doi.org/10.1007/s12011-015-0552-8.PubMedCrossRefGoogle Scholar
  45. 45.
    Yu I-T, Ju C-C, Lin J, Wu H-L, Yen H-T. Effects of probiotics and selenium combination on the immune and blood cholesterol concentration of pigs. J Anim Feed Sci. 2004;13(4):625–34.  https://doi.org/10.22358/jafs/67630/2004.CrossRefGoogle Scholar
  46. 46.
    Zholobak NM, Sherbakov AB, Babenko LS, Bogorad-Kobelska OS, Bubnov RV, Ivanov VK, et al. The perspectives of biomedical application of the nanoceria. EPMA J. 2014;5(Suppl 1):A136–2.  https://doi.org/10.1186/1878-5085-5-S1-A136.PubMedCentralCrossRefGoogle Scholar
  47. 47.
    Beregova TV, Neporada KS, Skrypnyk M, Falalyeyeva TM, Zholobak NM, Shcherbakov OB, et al. Efficacy of nanoceria for periodontal tissues alteration in glutamate-induced obese rats-multidisciplinary considerations for personalized dentistry and prevention. EPMA J. 2017;8(1):43–9.  https://doi.org/10.1007/s13167-017-0085-7.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Zholobak NM, Ivanov VK, Shcherbakov AB, Shaporev AS, Polezhaeva OS, Baranchikov AY, et al. UV-shielding property, photocatalytic activity and photocytotoxicity of ceria colloid solutions. J Photochem Photobiol B. 2011;102(1):32–8.  https://doi.org/10.1016/j.jphotobiol.2010.09.002.PubMedCrossRefGoogle Scholar
  49. 49.
    Yefimenko OY, Savchenko YO, Falalyeyeva TM, Beregova TV, Zholobak NM, Spivak MY, et al. Nanocrystalline cerium dioxide efficacy for gastrointestinal motility: potential for prokinetic treatment and prevention in elderly. EPMA J. 2015;6:6.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Kobyliak N, Virchenko O, Falalyeyeva T, Kondro M, Beregova T, Bodnar P, et al. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats. Biomed Pharmacother. 2017;90:608–14.  https://doi.org/10.1016/j.biopha.2017.03.099.PubMedCrossRefGoogle Scholar
  51. 51.
    Babenko LP, Zholobak NM, Shcherbakov AB, Woychuk SI, Lazarenko LM. Spivak MYa: Antimicrobial action of the ceria colloid solution on opportunistic microorganisms in vitro. Mikrobiol Zh. 2012;74(3):54–62.Google Scholar
  52. 52.
    Engeda JC, Holliday KM, Hardy ST, Chakladar S, Lin DY, Talavera GA, et al. Transitions from ideal to intermediate cholesterol levels may vary by cholesterol metric. Sci Rep. 2018;8(1):2782.  https://doi.org/10.1038/s41598-018-20660-2.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 2017;8(1):1785.  https://doi.org/10.1038/s41467-017-01682-2.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Tanaka H, Doesburg K, Iwasaki T, Mierau I. Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci. 1999;82:2530–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Ruiz L, Margolles A, Sánchez B. Bile resistance mechanisms in Lactobacillus and Bifidobacterium. Front Microbiol. 2013;4:396.  https://doi.org/10.3389/fmicb.2013.00396.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Nie YF, Hu J, Yan XH. Cross-talk between bile acids and intestinal microbiota in host metabolism and health. J Zhejiang Univ Sci B. 2015;16(6):436–46.  https://doi.org/10.1631/jzus.B1400327.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6:320–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis ofrandomised controlled trials. Nutr Metab Cardiovasc Dis. 2011;21(11):844–50.  https://doi.org/10.1016/j.numecd.2011.04.008.PubMedCrossRefGoogle Scholar
  59. 59.
    Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(43):e1714.  https://doi.org/10.1097/MD.0000000000001714.CrossRefGoogle Scholar
  60. 60.
    Ooi L-G, Liong M-T. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci. 2010;11(6):2499–522.  https://doi.org/10.3390/ijms11062499.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Wang J, Zhang H, Chen X, Chen Y. Menghebilige, Bao Q. Selection of potential probiotic lactobacilli for cholesterol-lowering properties and their effect on cholesterol metabolism in rats fed a high-lipid diet. J Dairy Sci. 2012;95(4):1645–54.PubMedCrossRefGoogle Scholar
  62. 62.
    Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial. Middle East J Dig Dis. 2017;9(3):150–7.  https://doi.org/10.15171/mejdd.2017.66.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    McPhee JB, Schertzer J. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. Clin Sci. 2015;129:1083–96.  https://doi.org/10.1042/CS20150431.PubMedCrossRefGoogle Scholar
  64. 64.
    Avishai E, Yeghiazaryan K, Golubnitschaja O. Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 2017;8(1):23–33.  https://doi.org/10.1007/s13167-017-0081-y.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Smokovski I, Risteski M, Polivka J Jr, Zubor P, Konieczka K, Costigliola V, et al. Postmenopausal breast cancer: European challenge and innovative concepts. EPMA J. 2017;8(2):159–69.  https://doi.org/10.1007/s13167-017-0094-6.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Hotamisligil GS. Inflammation and metabolic disorders. Nature. 200;444(7121):860–7 Review.CrossRefGoogle Scholar
  67. 67.
    Lazarenko LM, Babenko LP, Bubnov RV, Demchenko OM, Zotsenko VM, Boyko NV, et al. Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties. Mikrobiol Zh. 2017;79(1):66–75.CrossRefGoogle Scholar
  68. 68.
    Lazarenko L, Melnikova O, Babenko L, Bubnov R, Beregova T, Falalyeyeva T, et al. Lactobacillus and Bifidobacteria probiotic strains improve glycemic and inflammation profiles in obesity model in mice. Preprints. 2018.  https://doi.org/10.20944/preprints201808.0169.v1.
  69. 69.
    Chistoserdova L. Lanthanides: New life metals? World J Microbiol Biotechnol. 2016;32(8):138.  https://doi.org/10.1007/s11274-016-2088-2.PubMedCrossRefGoogle Scholar
  70. 70.
    Skovran E, Martinez-Gomez NC. Microbiology. Just add lanthanides. Science. 2015;348(6237):862–3.  https://doi.org/10.1126/science.aaa9091.PubMedCrossRefGoogle Scholar
  71. 71.
    Cai L, Nyachoti CM, Kim IH. Impact of rare earth element-enriched yeast on growth performance, nutrient digestibility, blood profile, and fecal microflora in finishing pigs. Can J Anim Sci. 2018;98:347–53.CrossRefGoogle Scholar
  72. 72.
    Oró D, Yudina T, Fernández-Varo G, Casals E, Reichenbach V, Casals G, et al. Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J Hepatol. 2016;64(3):691–8.  https://doi.org/10.1016/j.jhep.2015.10.020.PubMedCrossRefGoogle Scholar
  73. 73.
    Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the scavenging of reactive oxygen species (ROS): direct effect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis. Biomolecules. 2019;9(9).  https://doi.org/10.3390/biom9090425.PubMedCentralCrossRefGoogle Scholar
  74. 74.
    Malekkhaiat Häffner S, Malmsten M. Membrane interactions and antimicrobial effects of inorganic nanoparticles. Adv Colloid Interf Sci. 2017;248:105–28.  https://doi.org/10.1016/j.cis.2017.07.029.CrossRefGoogle Scholar
  75. 75.
    Frost R, Svedhem S. Characterization of nanoparticle-lipid membrane interactions using QCM-D. Methods Mol Biol. 2013;991:127–37.  https://doi.org/10.1007/978-1-62703-336-7_13.PubMedCrossRefGoogle Scholar
  76. 76.
    Contini C, Schneemilch M, Gaisford S, Quirke N. Nanoparticle–membrane interactions. J Exp Nanosci. 2018;13(1):62–81.  https://doi.org/10.1080/17458080.2017.1413253.CrossRefGoogle Scholar
  77. 77.
    Alpaslan E, Geilich BM, Yazici H, Webster TJ. pH-controlled cerium oxide nanoparticle inhibition of both Gram-positive and Gram-negative bacteria growth. Sci Rep. 2017;7:45859.  https://doi.org/10.1038/srep45859.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Pulido-Reyes G, Rodea-Palomares I, Das S, Sakthivel TS, Leganes F, Rosal R, et al. Untangling the biological effects of cerium oxide nanoparticles: the role of surface valence states. Sci Rep. 2015;5:15613.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Pelletier DA, Suresh AK, Holton GA, McKeown CK, Wang W, Gu B, et al. Effects of engineered cerium oxide nanoparticles on bacterial growth and viability. Appl Environ Microbiol. 2010;76(24):7981–9.  https://doi.org/10.1128/AEM.00650-10.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Kamika I, Tekere M. Impacts of cerium oxide nanoparticles on bacterial community in activated sludge. AMB Express. 2017;7:63.  https://doi.org/10.1186/s13568-017-0365-6.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Zholobak NM, Ivanov VK, Shcherbakov AB. Interaction of nanoceria with microorganisms. In: Grumezescu AM, editor. Nanobiomaterials in Antimicrobial Therapy. Bucharest: Elsevier Inc.; 2016. p. 419–50.  https://doi.org/10.1016/B978-0-323-42864-4.00012-9.CrossRefGoogle Scholar
  82. 82.
    Hickey MW, Hillier AJ, Jago GR. Transport and metabolism of lactose, glucose, and galactose in homofermentative lactobacilli. Appl Environ Microbiol. 1986;51(4):825–31.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Pol A, Barends TR, Dietl A, Khadem AF, Eygensteyn J, Jetten MS, et al. Rare earth metals are essential for methanotrophic life in volcanic mudpots. Environ Microbiol. 2014;16(1):255–64.PubMedCrossRefGoogle Scholar
  84. 84.
    Good NM, Vu HN, Suriano CJ, Subuyuj GA, Skovran E, Martinez-Gomez NC. Pyrroloquinoline quinone ethanol dehydrogenase in methylobacterium extorquens AM1 extends lanthanide-dependent metabolism to multicarbon substrates. J Bacteriol. 2016;198(22):3109–18.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Akagawa M, Minematsu K, Shibata T, Kondo T, Ishii T, Uchida K. Identification of lactate dehydrogenase as a mammalian pyrroloquinoline quinone (PQQ)-binding protein. Sci Rep. 2016;6:26723.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Li N, Duan Y, Zhou M, Liu C, Hong F. The effects of lanthanoid on the structure–function of lactate dehydrogenase from mice heart. Biol Trace Elem Res. 2009;132(1-3):164–75.PubMedCrossRefGoogle Scholar
  87. 87.
    Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM. Anti-inflammatory properties of cerium oxide nanoparticles. Small. 2009;5(24):2848–56.  https://doi.org/10.1002/smll.200901048.PubMedCrossRefGoogle Scholar
  88. 88.
    Fu H, Yuan J, Gao H. Microbial oxidative stress response: novel insights from environmental facultative anaerobic bacteria. Arch Biochem Biophys. 2015;584:28–35.  https://doi.org/10.1016/j.abb.2015.08.012 Review.PubMedCrossRefGoogle Scholar
  89. 89.
    Dickson I. Anaerobic intestine-on-a-chip system enables complex microbiota co-culture. Nat Rev Gastroenterol Hepatol. 2019;16(7):390.  https://doi.org/10.1038/s41575-019-0162-6.PubMedCrossRefGoogle Scholar
  90. 90.
    Carvajal S, Perramón M, Oró D, Casals E, Fernández-Varo G, Casals G, et al. Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. Sci Rep. 2019;9(1):1–20.CrossRefGoogle Scholar
  91. 91.
    Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules. 2019;9(9). pii: E425.  https://doi.org/10.3390/biom9090425.PubMedCentralCrossRefGoogle Scholar
  92. 92.
    Lye HS, Khoo BY, Karim AA, Rusul G, Liong MT. Ultrasound enhanced growth and cholesterol removal of Lactobacillus fermentum FTDC 1311 in the parent cells but not the subsequent passages. Ultrason Sonochem. 2012;19(4):901–8.  https://doi.org/10.1016/j.ultsonch.2011.12.018.].PubMedCrossRefGoogle Scholar
  93. 93.
    Lye HS, Alias KA, Rusul G, Liong MT. Ultrasound treatment enhances cholesterol removal ability of lactobacilli. Ultrason Sonochem. 2012;19(3):632–41.  https://doi.org/10.1016/j.ultsonch.2011.08.004.PubMedCrossRefGoogle Scholar
  94. 94.
    Lye HS, Karim AA, Rusul G, Liong MT. Electroporation enhances the ability of lactobacilli to remove cholesterol. J Dairy Sci. 2011;94(10):4820–30.  https://doi.org/10.3168/jds.2011-4426.PubMedCrossRefGoogle Scholar
  95. 95.
    Bubnov RV, Spivak MY. Sonoporation delivery of inorganic nanoparticles into bacterial cell of probiotic strains using diagnostic ultrasound machine. Ultrasound Med Biol. 2019;45:S83.  https://doi.org/10.1016/j.ultrasmedbio.2019.07.282.CrossRefGoogle Scholar
  96. 96.
    Мokrozub VV, Lazarenko LM, Sichel LM, Babenko LP, Lytvyn PM, Demchenko OM, Melnichenko YO, Boyko NV, Biavati B, DiGioia D, Bubnov RV, Spivak MY. The role of beneficial bacteria wall elasticity in regulating innate immune response. EPMA J. 2015;6(1):13.  https://doi.org/10.1186/s13167-015-0035-1.
  97. 97.
    Bubnov R, Babenko L, Lazarenko L, et al. Lactobacillus and Bifidobacterium strains and compositions with nanoceria reduce cholesterol levels in an obesity mouse model. EFSA congress 2018 in Parma, Italy. EFSA Journal 09/2018; 16(Suppl. 1):157. https://www.efsa.europa.eu/sites/default/files/event/180918-conference/conference18-EFSA_Journal_abstracts.pdf. (Accessed 25.10.2019).
  98. 98.
    Bubnov R, Spivak M. Towards Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome and Associated Diseases Treatment: Does Pathophysiology-Based Approach Work and Can Anticipated Evidence Be Completed?. Preprints 2018, 2018090185.  https://doi.org/10.20944/preprints201809.0185.v1.

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2019

Authors and Affiliations

  1. 1.Zabolotny Institute of Microbiology and VirologyNational Academy of Sciences of UkraineKyivUkraine
  2. 2.Clinical Hospital “Pheophania” of State Affairs DepartmentKyivUkraine
  3. 3.Radiological Clinic, UKBExcellence University of BonnBonnGermany
  4. 4.Breast Cancer Research Centre, UKBExcellence University of BonnBonnGermany
  5. 5.Centre for Integrated Oncology, Cologne-Bonn, UKBExcellence University of BonnBonnGermany
  6. 6.LCL ‘DIAPROF’KyivUkraine

Personalised recommendations